Aberrant Promoter Methylation of FBLN-3 Gene and Clinicopathological Significance in Non-Small Cell Lung Carcinoma

Strategic Insights -

A recent study has shed light on the relationship between the FBLN-3 gene and non-small cell lung carcinoma (NSCLC), a type of lung cancer that is often aggressive and difficult to treat. The research, published in the journal Lung Cancer, investigated the promoter methylation status of the FBLN-3 gene in NSCLC tissue samples and correlated it with various clinicopathological factors. The study found that 43.1% of NSCLC tissue samples showed promoter methylation of the FBLN-3 gene, whereas only 9.2% of corresponding non-tumor tissue samples did so.

Key Takeaways:

  • The FBLN-3 gene, which has been identified as an antagonist of angiogenesis, was found to be methylated in 43.1% of NSCLC tissue samples, suggesting its potential role in the progression of NSCLC.
  • The methylation of the FBLN-3 gene promoter was significantly more common in NSCLC tissue samples compared to corresponding non-tumor tissue samples, indicating its potential as a biomarker for early detection of NSCLC.
  • The loss of FBLN-3 gene expression induced by promoter methylation may play a crucial role in the progression of NSCLC.
  • The study suggests that FBLN-3 promoter methylation could be a promising biomarker for early detection of NSCLC.
  • R. Wang and colleagues from NanJing University, Department of Medical Oncology, conducted the study and published it in Lung Cancer in 2010.
  • The study highlights the importance of understanding the molecular mechanisms underlying NSCLC and the potential use of FBLN-3 promoter methylation as a biomarker for early detection and treatment of NSCLC.

Statistics:

  • 43.1% of NSCLC tissue samples showed promoter methylation of the FBLN-3 gene.
  • 9.2% of corresponding non-tumor tissue samples showed promoter methylation of the FBLN-3 gene.
  • The methylation of the FBLN-3 gene promoter was significantly more common in NSCLC tissue samples compared to non-tumor tissue samples (p < 0.05).

Sources:

  • Wang, R. et al. (2010). Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer, 69(2), 239-244.
  • Small Cell Carcinoma.
  • NewsRx.com (2010). Cancer Weekly.